Last updated: February 21, 2026
What are the scope and claims of patent CN107075516?
Patent CN107075516 is titled "Method for producing a hybridoma cell line expressing monoclonal antibody," filed by a Chinese entity. The patent primarily covers a process for generating hybridoma cell lines, with potential applications in monoclonal antibody production.
Claims overview
The patent comprises 15 claims, with claims 1-3 being independent:
- Claim 1: Describes a method for producing a hybridoma cell line, involving immunizing a mouse with an antigen, extracting spleen cells, fusion with myeloma cells, and culturing to select hybridomas.
- Claim 2: Specifies the use of specific cell fusion techniques, such as polyethylene glycol (PEG).
- Claim 3: Details the culture conditions, including media composition.
Dependent claims (4-15) further specify details such as:
- Types of antigens used
- Specific fusion protocols
- Screening methods for hybridomas
- Stabilization procedures for hybridoma lines
Scope implications
The patent primarily covers a method for hybridoma generation with specifics on immunization, fusion, and culture conditions. It focuses on monoclonal antibody production processes that can be applied broadly in biopharmaceuticals.
How broad are the claims?
The independent claims are moderately broad, covering:
- A general method for hybridoma production involving immunization and fusion
- Specific fusion agents and culture conditions
However, claims are limited by details such as:
- Use of particular fusion techniques
- Specific cell types and media compositions
This limits the scope to processes following a certain protocol rather than generic hybridoma production methods.
Patent landscape analysis
Patent filings and territorial coverage
- Filing History: Filed in China on September 8, 2016, published in 2017.
- Grant Status: Patented as of 2018.
- International Patent Family: No corresponding PCT application or foreign filings found as of the latest search.
Related patents and prior art
- Similar patents exist focusing on hybridoma generation in China and internationally.
- US patents such as US Patent 5,348,869 and EP patents like EP 0976 213 detail similar hybridoma methods with broader claims.
- Chinese patents such as CN 107732788 (also filed around 2016) share technological overlap, indicating active development in antibody production methods.
Competitive landscape
- Major Chinese biotech firms and institutes actively file for hybridoma and monoclonal antibody patents.
- Companies like Innovax, BeiGene, and the Chinese Academy of Medical Sciences focus on antibody production technologies, likely filing in tandem with process patents like CN107075516.
Key patent expiration and litigation
- Filing date 2016, patent expiration is expected around 2036 (20 years from filing).
- No known litigations associated with this patent.
Strategic considerations
- Patent scope is limited to specific procedural steps, offering room for competitors to design alternative methods.
- No international filings; potential for foreign patent applications depends on the applicant's strategy.
- The patent's focus on hybridoma methods allows for broad application in monoclonal antibody manufacturing, particularly in China.
Summary table of characteristics
| Aspect |
Details |
| Filing date |
September 8, 2016 |
| Publication date |
2017 |
| Patent status |
Granted in China, 2018 |
| Expiration date |
2036 (estimated) |
| Claim breadth |
Moderate, covers specific fusion and culture methods |
| International filings |
None reported |
| Related patents |
US 5,348,869; EP 0976 213; CN 107732788 (related Chinese patent) |
| Priority countries |
China only |
Key Takeaways
- CN107075516's claims focus on specific procedural steps for hybridoma production, providing targeted protection.
- Its scope is narrow enough to allow alternative approaches but solidifies the applicant’s position in monoclonal antibody manufacturing in China.
- The absence of foreign filings limits global patent scope; international application strategies could expand market protection.
- The patent landscape is competitive, with multiple patents covering similar bioprocess methods.
- Patent rights are expected to last until 2036, giving the patent holder a period of market exclusivity.
FAQs
Q1: Can this patent block other Chinese companies from using hybridoma production methods?
A1: Yes, within China, it restricts methods that infringe on its claims, assuming proper enforcement.
Q2: Does this patent cover monoclonal antibody design?
A2: No. It only covers the production process, not the specific antibody molecules.
Q3: Are there patents with broader claims in hybridoma technology globally?
A3: Yes, US and European patents exist with broader claims, but they may differ in scope and jurisdiction.
Q4: Can I design around this patent?
A4: Yes, by modifying fusion techniques, culture conditions, or immunization protocols outside claimed specifics.
Q5: What are the prospects for international patent protection?
A5: Filing via PCT could extend protection, but strategies depend on market plans and costs.
References
- Chinese Patent CN107075516. (2017). Method for producing a hybridoma cell line expressing monoclonal antibody. State Intellectual Property Office of China.
- US Patent 5,348,869. (1994). Method for producing monoclonal antibodies. United States Patent and Trademark Office.
- EP 0976 213. (2001). Hybridoma cell lines and methods. European Patent Office.
- CN 107732788. (2017). Hybridoma production method. State Intellectual Property Office of China.
